Table of Contents Table of Contents
Previous Page  161 / 280 Next Page
Information
Show Menu
Previous Page 161 / 280 Next Page
Page Background

Medical Sciences and Newcastle Hospital’s NHS Foundation Trust have

been performing pioneering research into NAFLD for the past 25 years,

making a number of important discoveries that have influenced patient

management worldwide.

“This exciting project builds on this body of work and provides a fantastic

opportunity to better understand this complex disease and therefore

develop better prevention and treatment strategies for the growing

number of patients developing and succumbing to the more serious

forms of the disease, such as liver cirrhosis and cancer.”

More than 350 research projects working across a variety of common

diseases applied for a Horizon 2020 grant in this round of funding, with

only the best 2.5% securing money. After evaluation by independent

experts, the EPoS project was ranked as one of the top proposals and

was recognised for its clear, pertinent, comprehensive objectives and

high standards of excellence.

One of the goals of EU-funded research is realising new breakthroughs

to benefit the health of EU citizens. Through this Horizon 2020 project,

the European Commission is accomplishing this goal whilst tackling one

of the major growing health burdens not just in Europe but in the entire

Western world.

using technologies to integrate all the

information and model the disease biology. This

is the first time that such a detailed analysis will

be performed on a single large group of people.

According to Anstee, patients involved in the

project will be some of the most highly

characterised individuals ever.

Key partners

The EPoS project consortium comprises

investigating partners from across Europe. In

addition to the participation of Newcastle

University as well as the University of

Cambridge and iXscient in the UK, also involved

are the Institute of Cardiometabolism and

Nutrition in Paris, France; the University of Turin

and the University of Florence, Italy; University

of Helsinki, Finland; Steno Diabetes Center and

Nordic Bioscience, Denmark; and Johannes

Gutenberg-Universität Mainz, Germany.

Among the Newcastle University research team

is renowned liver expert Professor Chris Day,

pro-vice-chancellor of Newcastle University’s

Faculty of Medical Sciences. Commenting on

the project, the leading researcher said: “The

Liver Group in Newcastle University’s Faculty of

B R OW S E

www.ncl.ac.uk

H O R I Z O N

2 0 2 0

www.horizon2020projects.com

H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L

I S S U E S E V E N

161

M E TA B O L I C D I S E A S E S

Living with NAFLD

To provide an insight into living with NAFLD, Newcastle University

published the thoughts of Penny Anderson, a 68-year-old

grandmother in the UK who was diagnosed with NAFLD more than a

decade ago. Although not certain, suffering with Type 2 diabetes is

likely to have led to her development of the disease.

Anderson, who lives in Whitley Bay, North Tyneside, has welcomed

the groundbreaking research led by Newcastle University.

Commenting, she said: “I’m so excited that this research is being

undertaken as it offers real hope to people with NAFLD that there

will be new treatments identified for this condition in the future.

“It’s absolutely wonderful that this research is going to help not just

me but lots of other people with NAFLD, and I’m all for studies that

gain a better understanding into this disease.”

Adding his thoughts, the chairman of the local charity LIVErNORTH,

John Bedlington, said: “LIVErNORTH has supported research into

liver disease since our foundation more than 20 years ago. We are

very supportive of the European study of NAFLD, which we believe

is not only timely but very necessary. We are confident that there

will be some very positive outcomes from this research which will

prove to be of benefit to liver patients, their carers, families, and to

public health.”

Obesity is a key

contributing factor

to the development

of NAFLD